Xenetic Biosciences (XBIO) Non-Current Assets (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Non-Current Assets came in at $313921.0 in Q1 2026, little changed YoY from $313921.0 in Q1 2025, and little changed on a QoQ basis from $313921.0 in Q4 2025.
Xenetic Biosciences (XBIO) Non-Current Assets (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Non-Current Assets data on file, last reported at $313921.0 in Q1 2026.
- Quarterly Non-Current Assets changed 0.0% year-over-year to $313921.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $627842.0 (down 76.44% YoY) and the FY2025 annual result came in at $313921.0, changed 0.0% from the prior year.
- Non-Current Assets was little changed at $313921.0 in Q1 2026, from $313921.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.4 million in Q3 2022 to a low of $313921.0 in Q4 2024.
- A 5-year average of $816126.7 and a median of $1.0 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 99.57% — and 2024, when it slumped 69.17%.
- Tracing XBIO's Non-Current Assets over 5 years: stood at $1.1 million in 2022, then decreased by 4.55% to $1.0 million in 2023, then sank by 69.17% to $313921.0 in 2024, then changed by 0.0% to $313921.0 in 2025, then changed by 0.0% to $313921.0 in 2026.
- The last three Non-Current Assets figures came in at $313921.0 (Q1 2026), $313921.0 (Q4 2025), and $313921.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | 313,921.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 313,921.00 |
| Mar 31, 2026 | 313,921.00 |
| Dec 31, 2025 | 313,921.00 |
| Mar 31, 2025 | 313,921.00 |
| Dec 31, 2024 | 313,921.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 704,431.00 |
| Jun 30, 2023 | 704,431.00 |
| Mar 31, 2023 | 844,431.00 |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.09 Mn |
| Dec 31, 2021 | 1.09 Mn |
| Sep 30, 2021 | 704,430.00 |
| Jun 30, 2021 | 715,898.00 |
| Mar 31, 2021 | 725,509.00 |